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Background: Abnormal fatty acid metabolism is an important feature in the mechanisms of insulin resistance and b-cell
dysfunction. Carnitine palmitoyltransferase-1a (CPT-1a, liver isoform) has a pivotal role in the regulation of mitochondrial fatty
acid oxidation. We investigated the role of CPT-1a in the development of impaired glucose tolerance using a mouse model
for CPT-1a deficiency when challenged by either a high-carbohydrate (HCD) or a high-fat diet (HFD) for a total duration of up to
46 weeks.
Methods: Insulin sensitivity and glucose tolerance were assessed in heterozygous CPT-1a-deficient (CPT-1aþ/ ) male mice
after being fed either a HCD or a HFD for durations of 28 weeks and 46 weeks. Both glucose and insulin tolerance tests were
used to investigate b-cell function and insulin sensitivity. Differences in islet insulin content and hepatic steatosis were evaluated
by morphological analysis.
Results: CPT-1aþ/  mice were more insulin-sensitive than CPT-1aþ/þ mice when fed either HCD or HFD. The increased
insulin sensitivity was associated with an increased expression of Cpt-1b (muscle isoform) in liver, as well as increased
microvesicular hepatic steatosis compared with CPT-1aþ/þ mice. CPT-1aþ/  mice were more glucose tolerant than CPT-
1aþ/þ mice when fed the HCD, but there was no significant difference when fed HFD. Moreover, CPT-1aþ/  mice fed HFD
or HCD had fewer and smaller pancreatic islets than CPT-1aþ/þ mice.
Conclusions: CPT-1a deficiency preserved insulin sensitivity when challenged by long-term feeding of either diet. Furthermore,
CPT-1a-deficient mice had distinct phenotypes dependent on the diet fed demonstrating that both diet and genetics collectively
have a role in the development of impaired glucose tolerance.
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Introduction
Impaired glucose tolerance is considered to be the earliest
identifiable metabolic abnormality in the pathogenesis of
Type 2 diabetes.
1 Glucose tolerance is thought to be a
function of both b-cell responsiveness to increased blood
glucose concentration and peripheral tissue responsiveness
to insulin.
2,3 Many metabolic phenotypes are influenced
by a combination of genotype and environment, particularly
the diet.
Aberrant mitochondrial fatty acid oxidation (FAO) may
have a pivotal role in the development of impaired glucose
tolerance.
4–6 Carnitine palmitoyltransferase-1 (CPT-1) func-
tions as the rate-limiting step of FAO. This enzyme is
responsible for converting long-chain acyl-CoAs into long-
chain acylcarnitines, a process required for translocation
across the mitochondrial membrane into the mitochondrial
matrix where b-oxidation occurs. A build-up of fatty acid
metabolites, including long-chain fatty acyl-CoAs and
diacylglycerols in the cytosol of skeletal muscle and other
tissues has been implicated in fatty acid-induced insulin
resistance.
4 Moreover, studies in rodents have shown that Received 28 February 2011; revised 20 June 2011; accepted 10 July 2011
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7–12
We have previously demonstrated a range of metabolic
phenotypes in mice with inherited deficiencies of other
mitochondrial FAO enzymes.
13,14
Our aim was to systematically investigate factors thought
to be involved in the development of insulin resistance and
Type 2 diabetes by challenging both CPT-1aþ/þ or
CPT-1aþ/  mice with a high-carbohydrate diet (HCD) or a
high-fat diet (HFD) diet and evaluate them at an age more
similar to human middle age. The rationale behind the HCD
challenge was to induce conditions that would promote high
levels of malonyl-CoA, a potent CPT-1 inhibitor.
15 Our aim
in using the HFD was to challenge this impaired CPT-1
system with excess substrate to promote build-up of fatty
acids. We hypothesized that both the HCD-induced increase
in the CPT-1a inhibitor, malonyl-CoA, as well as the
HFD-induced substrate overload, would unmask a pheno-
type in a mouse model with a genetically compromised state
of FAO. Furthermore, we expected to demonstrate that the
combination of chronic environmental stresses of diet and
the genetic limitation of FAO by decreased CPT-1a activity
would lead to one or all of the metabolic abnormalities
associated with the development of Type 2 diabetes.
Materials and methods
Animals
Male mice with a heterozygous deficiency in CPT-1a (CPT-
1aþ/  mice) (129S6/SvEvTac-coisogenic background) were
previously described.
16 Homozygous CPT-1a-deficient mice
are not viable.
16 Two separate, age-matched (CPT-1aþ/þ
and CPT-1aþ/ ) groups of mice were maintained on either a
HFD or HCD for either 28 or 46 weeks. All mice were housed
in a pathogen-free facility (12-h light/12-h dark cycle). All
experiments were approved by the Institutional Animal Care
and Use Committee of the University of Alabama at
Birmingham.
Diets, body weight and body composition analyses
Mice were fed either a HFD (Teklad diet-TD 97268) contain-
ing 43% fat (calorie %) using beef tallow as the major fat
source, or a HCD (Teklad diet-TD 97267) that was 14% fat,
with starch making up the bulk of calories. Both diets were
isocaloric and contained equal amounts of sucrose. Mice
(17- to 19-day-olds) were weaned onto their respective diets
and fed ad libitum. Body weights were determined weekly
using a standard balance. Body composition was determined
at the end of the study period using dual-energy X-ray
absorptometry, as described previously.
17,18
Serum metabolite assays
Mice were fasted for 20–22h before collection of serum. Total
non-esterified fatty acids were measured by an enzymatic,
colorimetric method (‘NEFA-C’ reagents, Wako Diagnostics,
Richmond, VA, USA). Triglyceride concentrations were mea-
sured in 10ml sera with the Ektachem DT II system (Johnson
and Johnson Clinical Diagnostics, Rochester, NY, USA).
Glucose tolerance tests
The oral glucose tolerance test outcomes of interest included
basal (fasted) serum glucose concentration, glucose and
insulin concentrations at individual time points following
glucose ingestion. From these data, the rate of decline of
blood glucose was determined.
At 20h before performing oral glucose tolerance test,
animals were food-deprived with water overnight. After the
mice were weighed, a baseline blood sample was obtained by
tail bleed, and additional blood samples were obtained at 15,
30, 60 and 120min following oral glucose administration at
2.0mg per g body weight.
Insulinogenic index calculations were made to assess
differences in first-phase insulin secretion. The formula used
is ((insulin) 30min (insulin) 0min)/((glucose) 30min 
(glucose) 0min).
19 This represents the change in insulin
level at 30min after glucose administration divided by the
change in glucose level 30min after the oral dose of glucose.
Insulin tolerance tests
Mice were deprived of food for 4h, baseline blood samples
were collected and recombinant human insulin (Humulin R,
100Uml
 1 stock) was injected intraperitoneally (0.1ml per
10g body weight). Before injection, insulin was diluted in
saline to a concentration of 0.075Uml
 1 (1:1330). Addi-
tional blood samples were obtained at 10, 20 and 30min,
following insulin injection. Outcomes of interest included
the final (30min) glucose concentration, and the rate of
decline of glucose, which was calculated from the slope of
the descending points after insulin injection. The rate of
decline of blood glucose was determined to be a reflection of
the degree of insulin sensitivity.
Blood glucose concentrations were measured with a blood
glucose meter (Accu-chek; Roche Diagnostics, Indianapolis,
IN, USA), and serum insulin levels were measured with a rat
sensitive immunoassay kit (LINCO Research, St Charles, MO,
USA) with a 1:10 dilution of mouse serum used as per the
manufacturer’s instructions.
RNA extraction and real-time quantitative RT-PCR analysis
Total RNA was extracted from heart, liver and skeletal muscle
(soleus and gastrocnemius) using TRIzol (Invitrogen Life
Technologies, Carlsbad, CA, USA). First-strand cDNA was
generated from 5mg of RNA in a 20ml volume reaction
containing both oligo-(dT) and random hexamers
(Invitrogen First-Strand Synthesis Kit). Real-time quantita-
tive RT-PCR (QRT-PCR) was carried out in a 20ml reaction
volume containing 10ml supermix UDG (Invitrogen Life
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Nutrition and DiabetesTechnologies Inc.), 2ml cDNA, 0.2mM LUX Cpt-1a and 1b,
primer forward, 0.2mM LUX Cpt-1a and 1b, primer reverse
(FAM-labeled, Invitrogen Life Technologies), 0.1mM 18S RNA
primer forward, 0.1mM 18S RNA primer reverse (JOE-labeled,
Invitrogen, Life Technologies). Cycling conditions included
incubation at 501C for 2min, a 2min 951C denaturing step,
followed by 44 cycles of 951C denaturation, 45s annealing
time at 581C and a 30s extension step at 721C. A melting
curve analysis was completed following amplification from
55–951C to assure product identification and homogeneity.
Each sample was normalized to the housekeeping gene
actin to compensate for any differences in starting quantity
of total RNA. The relative quantification for Cpt-1b and
Cpt-1a mRNA in CPT-1aþ/  compared with CPT-1aþ/þ
was calculated using the DDCt¼2 exp (DCt sample
(CPT-1aþ/ ) DCt reference (CPT-1aþ/þ))
20 where Ct
is the cycle number when threshold fluorescence is
significantly above background. The fold-change is then
established by comparing CPT-1aþ/  sample (relative
quantification¼calculated DDCt) against CPT-1aþ/þ refer-
ence (relative quantification¼1).
Histology and morphometric analyses of liver and pancreas
Liver and pancreas were collected from mice fasted for 24h
who had been fed a HCD or HFD for 46 weeks, processed
routinely for paraffin sectioning and stained with hematox-
ylin and eosin. Hepatocellular fatty change was assessed by
subjective scoring. The evaluator examined the slides with-
out knowledge of genotype or diet classification. Micro-
vesicular and macrovesicular fatty changes, each were scored 0
for normal/absent, 1 for mild, 2 for moderate and 3 for
severe, using increments of 0.5 for intermediate degrees.
Estimated distribution of each type of change was scored
1 for up to 1/4 of the section, 2 for 1/4 to 1/2, 3 for 1/2 to 3/4
or 4 for 3/4 to all of the section. Severity scores for
microvesicular and macrovesicular fatty changes were deter-
mined by multiplying the scores of severity and distribution
and were summed for a total severity score. Size and numbers
of islets in immunohistochemically stained sections of
pancreas were determined by histomorphometry. Images of
each section were made at  1 with a Nikon Super CoolScan
5000ED scanner (Melville, NY, USA) at 4000 pixels per inch.
For each section, the total area of pancreas and the area of
each immunostained islet were determined with Image-Pro
Plus 5.1 image analysis software (Media Cybernetics, Silver
Spring, MD, USA), and average islet area in mm
2, number of
islets per mm
2 pancreas, and the ratio of total islet area to
pancreas area were calculated.
Immunohistochemistry
Paraffin sections of pancreas were stained for insulin
according to a modification of a previously reported
method.
21 Briefly, endogenous peroxides were blocked with
0.3% hydrogen peroxide in phosphate-buffered saline for
30min. Background staining was decreased by blocking with
1% bovine serum albumin in phosphate-buffered saline for
1h. Anti-pig insulin (Sigma-Aldrich, St Louis, MO, USA)
developed in guinea pig, was used as the primary antibody at
1:9000 dilution and incubated for 2h in a humidity chamber
at room temperature. Anti-guinea pig IgG (whole molecule)
peroxidase conjugate (Sigma-Aldrich) at 1:1000 dilution was
used for the secondary antibody and incubated for 30min at
room temperature in a humidity chamber. True blue
peroxidase substrate (Kierkegaard and Perry Laboratories,
Gaithersburg, MD, USA) was applied for 10min and washed
in water for 3min. Sections were counterstained with
Nuclear Fast Red (Vector Labs, Burlingame, CA, USA) for
10min followed with a 3min wash in water, then air-dried
and coverslipped with Permount (Fisher Chemicals,
Fairlawn, NJ, USA).
Statistics
All data were expressed as mean values with s.e.m. Student’s
t-tests and two-way analysis of variance were used to analyze
effects of genotype and diet. Liver macrovesicular and
microvesicular fat scores were analyzed using the Kruskal–
Wallis test, the rank-sum test with Tukey’s probability
correction for multiple comparisons, and analysis of variance
of ranks. P-values o 0.05 were considered significant.
Results
Clinical markers for insulin resistance, impaired glucose
tolerance and Type 2 diabetes
We evaluated clinical markers of obesity, insulin resistance
and Type 2 diabetes such as body weight, body fat and liver
fatty change in CPT-1aþ/  mice as compared with the
CPT-1aþ/þ mice fed either HCD or HFD.
Using dual-energy X-ray absorptometry analysis, body fat
was significantly greater in CPT-1aþ/  mice fed HCD for 46
weeks than for CPT-1aþ/þ mice (P¼0.0241) (Figure 1a),
although there were no significant differences in body
weight of CPT-1aþ/  mice (Figure 1c) as compared with
CPT-1aþ/þ mice.
In contrast to the findings on the HCD, body fat was
significantly greater in CPT-1aþ/þ mice fed HFD for 46
weeks compared with CPT-1aþ/  mutants (P¼0.00019)
(Figure 1b). The body weights of the oldest CPT-1aþ/  mice
were significantly lower than CPT-1aþ/þ mice eating HFD
(Figure 1d).
Fasting serum glucose, insulin, triglycerides and free
fatty acids were evaluated in mice challenged with either a
HCD or HFD for either 28 or 46 weeks (Table 1). CPT-1aþ/ 
mice fed HFD had significantly higher serum glucose values
at 28 weeks; however, there were no other significant
differences in fasting glucose values as compared with
CPT-1aþ/þ mice fed either diet. Fasting insulin levels
were significantly lower (28 weeks P¼0.01; 46 weeks
P¼0.03) in HFD-fed CPT-1aþ/  mice as compared with
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Nutrition and DiabetesFigure 1 Effect of diet and CPT-1a deficiency on body weight and body-fat percentage over 46 weeks. (a) Body fat percentages in CPT-1aþ/  mice (n¼17) fed a
HCD as compared with CPT-1aþ/þ mice (n¼16). (b) Body fat percentages in CPT-1aþ/  mice fed a HFD (n¼16) as compared with CPT-1aþ/þ mice (n¼19).
(c) Body weights for CPT-1aþ/  (n¼19) versus CPT1aþ/þ (n¼17) mice fed HCD for 46 weeks. (d) Body weights for CPT-1aþ/  (n¼18) versus CPT1aþ/þ
(n¼20) mice fed HFD for 46 weeks reached significant differences during the final 8 weeks (*Po0.05, **Po0.01).
Table 1 Serum metabolites and insulin concentrations
Fasted CPT-1a+/  Fed CPT-1a+/  Fasted CPT-1a+/+ Fed CPT-1a+/+
Serum glucose mmoll
 1
HFD, 28 weeks n¼8 3.66±0.54* n¼10 3.00±0.61* P¼0.03
HFD, 46 weeks n¼9 3.27±1.3 n¼9 3.11±0.83
HCD, 28 weeks n¼9 3.22±0.88 n¼10 3.83±2.72
HCD, 46 weeks n¼9 2.83±0.67 n¼10 2.78±0.61
Serum insulin pmoll
 1
HFD, 28 weeks n¼13 36.1±10* n¼11 63.7±33* P¼0.01
HFD, 46 weeks n¼9 32.7±13* n¼8 63.7±36* P¼0.03
HCD, 28 weeks n¼10 27.5±14 n¼10 75.7±75
HCD, 46 weeks n¼9 27.5±1.7 n¼9 36.1±15
Triglycerides mmoll
 1
SRD, 24–32 weeks n¼7 1.59±0.73 1.19±0.30* n¼7 1.56±0.41 1.90±0.55* P¼0.01
HFD, 46 weeks n¼10 1.65±0.32 n¼13 1.58±0.43
HCD, 46 weeks n¼12 1.76±0.63 n¼11 1.63±0.25
Serum free fatty acids mmoll
 1
SRD, 24–32 weeks n¼71 . 6 ±0.38 0.90±0.2* n¼71 . 6 ±0.30 1.3±0.20* P¼0.018
HFD, 46 weeks n¼10 0.82±0.23 n¼13 0.98±0.24
HCD, 46 weeks n¼12 1.2±0.040 n¼11 0.91±0.24
Abbreviations: CPT, carnitine palmitoyltransferase; HCD, high-carbohydrate diet; HFD, high-fat diet; SRD, standard rodent diet. Fasting glucose and insulin for
CPT-1a+/  and CPT-1a+/+ fed HFD or HCD for 28 weeks or 46 weeks. Fasting and fed (SRD only) free fatty acids and triglycerides for mice fed SRD for 24–32 weeks,
HFD and HCD for 28 or 46 weeks.
Figure 2 Effects of diet on glucose and insulin tolerance in CPT-1aþ/  mice after 28 weeks. (a–c) Glucose levels (**Po0.01, ***Po0.001), insulin levels and
insulinogenic indexes (**P¼0.0038) throughout glucose tolerance test in CPT-1aþ/  (n¼10) versus CPT-1aþ/þ (n¼10) mice fed HCD. (d) Insulin tolerance
test. Slopes for the rate of decline of glucose (**Po0.002) in response to an intraperitoneal injection of insulin for CPT-1aþ/  (n¼8) and CPT-1aþ/þ (n¼8) mice
fed HCD. (e–g) Glucose levels, insulin levels and insulinogenic indexes (*P¼0.026) throughout glucose tolerance test in CPT-1aþ/  (n¼8) versus CPT-1aþ/þ
(n¼11) mice fed HFD. (h) Insulin tolerance test. Slopes for the rate of decline of glucose (*Po0.0439) in response to an intraperitoneal injection of insulin for
CPT-1aþ/  (n¼8) and CPT-1aþ/þ (n¼8) mice fed HFD.
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Nutrition and DiabetesCPT-1aþ/þ mice, suggesting a state of increased insulin
sensitivity. In contrast, there were no significant differences
in fasting insulin values among either group fed the HCD.
There were no significant differences in fasting serum
triglycerides or free fatty acids between CPT-1aþ/þ and
þ/  mice fed either diet.
Glucose tolerance
The 28-weeks-HCD group of CPT-1aþ/  mice were more
glucose tolerant than CPT-1aþ/þ mice, as measured by oral
glucose tolerance test (28 weeks, HCD); however, these
marked differences were lost by 46 weeks (Figures 2a and 3a).
Insulin levels, measured throughout oral glucose tolerance
tests, were not significantly different between genotypes
(Figures 2b and 3b). However, in the 28-weeks groups,
CPT-1aþ/  mice had significantly higher average first-phase
insulin responses to a glucose load, based on insulinogenic
index values (Figure 2c), indicating heightened b-cell
responsiveness (28-weeks-HCD P¼0.0038). In addition, in
the 46-weeks diet-duration groups there was a trend toward
higher average first-phase insulin responses to a glucose
load (Figure 3c), however, this difference did not reach
significance.
In the 28- and 46-weeks-HFD group, there was no
significant difference in glucose tolerance between CPT-
1aþ/  and CPT-1aþ/þ mice (Figures 2e and 3e). In
addition, first-phase insulin secretion, expressed by the
insulinogenic index, was significantly lower in CPT-1aþ/ 
mice (P¼0.0256) fed the HFD for 28 weeks (Figure 2g).
However, first-phase insulin secretion in the longer HFD
duration was not significantly different (Figure 3f) between
CPT-1aþ/  and CPT-1aþ/þ mice.
In summary, when fed the HCD for 28 weeks, the
CPT-1aþ/  mice were more glucose tolerant. Moreover,
these mice showed higher estimated first-phase insulin
secretion, which may partially explain their improved
glucose tolerance. In contrast, CPT-1aþ/  mice fed the
HFD were no less glucose tolerant than CPT-1aþ/þ mice.
Insulin tolerance
HCD-fed CPT-1aþ/  mice were significantly more insulin-
sensitive (28-weeks-HCD Po0.002, 46-weeks-HCD
Po0.0088) (Figures 2d and 3d) than were CPT-1aþ/þ
controls as was found by their steeper rate of decline of
blood glucose levels in response to insulin. In fact, the
standard protocol had to be modified because the CPT-1aþ/ 
mice became hypoglycemic. In addition, HFD-fed CPT-1aþ/ 
mice were significantly more insulin-sensitive (28-weeks-
HFD P¼0.0439 and 46-weeks-HFD P¼0.0129) (Figures 2h
and 3h) than CPT-1aþ/þ controls as shown by their steeper
rate of decline (negative slope) of blood glucose levels in
response to insulin.
Morphometric analysis of b-cells within islets
CPT-1aþ/  mice fed HCD for 46 weeks had lower percent islet
area/pancreas area (Pp0.001), lower total islet area (Pp0.001)
and lower average islet area (Pp0.001) (Figures 4a–c and g).
CPT-1aþ/  mice fed HFD for 46 weeks, also had lower percent
islet area/pancreas area (P¼0.006), lower total islet area
(Po0.005) and lower total islet number (P¼0.001) (Figures
4d–f and h). In summary, CPT-1aþ/  mice fed either of the
diet had significantly fewer insulin positive cells. The only
differences between the two diets were that the CPT-1aþ/ 
mice fed HCD had lower average islet area, indicating that
their islets were smaller overall, whereas HFD-fed CPT-1aþ/ 
mice had a lower number of islets overall.
Hepatic steatosis
CPT-1aþ/  mice fed either of the challenge diets demon-
strated significantly higher total (macro plus microvesicular
combined) fatty change (P¼0.01) scores than CPT-1aþ/þ
controls (Table 2 and Figures 5a and c). Microvesicular fat
scores in mice fed either of the diets were significantly higher
than macrovesicular fat scores, independent of genotype
(P¼0.003) (Table 2). Microvesicular fat scores were signifi-
cantly higher in CPT-1aþ/  mice when fed either diet as
compared with CPT-1aþ/þ mice (P¼0.03) (Figures 5a–d,
Table 2). Microvesicular liver steatosis is common in
b-oxidation disorders.
Analysis of steady state mRNA levels by northern blot
Northern blot results showed a striking Cpt-1b mRNA
expression in liver of CPT-1aþ/  mice as compared with
CPT-1aþ/þ mice fed a HCD (data not shown). Cpt-1a
expression was lower in CPT-1aþ/  mice as was expected
because of the targeted mutation (data not shown). To
further evaluate Cpt-1a and b mRNA expression, we used the
more quantitative and sensitive method of quantitative real-
time PCR (QRT-PCR).
QRT-PCR analysis of steady-state mRNA levels
CPT-1aþ/  mice fed HCD showed significantly higher
Cpt-1b expression in liver as measured by QRT-PCR than
Figure 3 Effects of diet on glucose and insulin tolerance in CPT-1aþ/  mice after 46 weeks. (a–c) Glucose levels, insulin levels and insulinogenic indexes throughout
glucose tolerance test in CPT-1aþ/  (n¼11) versus CPT-1aþ/þ (n¼10) mice fed HCD. (d) Insulin tolerance test. Slopes for the rate of decline of glucose (**P¼0.0088)
in response to an intraperitoneal injection of insulin for CPT-1aþ/  (n¼6) and CPT-1aþ/þ (n¼9) mice fed HCD. (e–g) Glucose levels, insulin levels and insulinogenic
indexes throughout glucose tolerance test in male CPT-1aþ/  (n¼9) versus CPT-1aþ/þ (n¼9) mice fed HFD. (h) Insulin tolerance test. Slopes for the rate of decline of
glucose (*P¼0.0129) in response to an intraperitoneal injection of insulin for CPT-1aþ/  (n¼8) and CPT-1aþ/þ (n¼8) mice fed HFD.
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CPT-1aþ/  mice showed a trend toward higher Cpt-1b
expression in liver as measured by QRT-PCR than CPT-1aþ/þ
controls, although the differences were not significant
(Figure 5f).
In conclusion of the results section, Table 3 summarizes
and provides a contrast of the overall results reported here.
Discussion
We hypothesized that the long-term effects of a high-calorie
diet coupled with a deficiency in mitochondrial FAO (CPT-1a
deficiency) would lead to both insulin resistance and b-cell
dysfunction, pivotal features in development of Type 2
diabetes. This initial hypothesis was based on previous
studies using CPT-1 inhibitors,
5,6,12 results from earlier
studies in our group showing the effects of another FAO
deficiency, long-chain acyl-CoA dehydrogenase,
13 and other
studies associating excess fatty acids with development of
insulin resistance and b-cell dysfunction.
4,7,10
We metabolically challenged the CPT-1aþ/  mice with
diets either high in fat (HFD) or high in carbohydrates (HCD)
to promote for conditions favorable to the generation of
malonyl-CoA, a potent inhibitor of CPT-1 activity. Post
transcriptionally, CPT-1b (muscle isoform) is regulated solely
by changes in malonyl-CoA levels, whereas CPT-1a, the
hepatic isoform (CPT-1a) is regulated by both concentrations
of and changes in sensitivity to malonyl-CoA.
15,22 Thus,
CPT-1a is unique in that it responds to physiological states
such as starvation, insulin deficiency and hypo- and
hyperthyroidism by changing its sensitivity to malonyl
CoA.
22
Figure 4 Islet morphology in mice fed a HCD versus a HFD. Differences in (a) % islet to pancreas area (***Pp0.001), (b) total islet area (***Pp0.001) and mean
islet area (c) (***Pp0.001) in CPT-1aþ/  (n¼7) versus CPT-1aþ/þ (n¼9) mice fed a HCD. There were no significant differences in average islet number (data not
shown). Differences in (d) % islet to pancreas area (**P¼0.006), (e) total islet area (**Po0.005) and (f) average islet number (***P¼0.001) in mice fed a HFD. There
were no significant differences in mean islet area (data not shown). CPT-1aþ/  mice (n¼10) and CPT-1aþ/þ mice (n¼7). Representative images of mouse islet
number and size in CPT 1aþ/  (g) and CPT-1aþ/þ (h) mouse pancreas sections from mice fed the HCD.
Table 2 Liver steatosis in mice fed high-carbohydrate diet or high fat diet for 46 weeks
CPT-1a+/+ (HCD) CPT-1a+/  (HCD) CPT-1a+/+ (HFD) CPT-1a+/  (HFD)
Macrovesicular fat 3.5±3.9 4.7±3.3 2±2.2 1.9±1.5
Microvesicular fat 2.4±4.2 10.1±10* 2.3±3.6 6.5±7.9*
Total 5.9±7.6 14.8±9.6* 4.3±4.9 8.5±7.3*
Abbreviations: CPT, carnitine palmitoyltransferase; HCD, high-carbohydrate diet; HFD, high-fat diet. CPT-1a+/  (n¼22), CPT-1a+/+ (n¼21) mice fed either diet
demonstrated significantly higher total (macro plus microvesicular combined) fatty change (P¼0.01) as compared with CPT-1a+/+ controls. Microvesicular fat was
significantly higher in CPT-1a+/  mice when fed either diet as compared with CPT-1a+/+ mice (P¼0.03). Microvesicular fat was significantly greater than
macrovesicular fat in mice fed the HCD, independent of genotype (P¼0.003).
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study showing that rats fed a high-fat or low-fat diet with
etomoxir (a CPT-1 inhibitor) were significantly less insulin-
sensitive than untreated rats.
5 However, our most striking
and consistent finding was that the CPT-1aþ/  mice were
more insulin-sensitive than CPT-1aþ/þ mice, when fed
either a HCD or HFD, as shown by both insulin tolerance
and fasting insulin levels. These results are contrary to our
initial hypothesis. We considered the possibility that our
results could be explained by the increased Cpt-1b expression
in the liver in CPT-1aþ/  mice. This mechanism may be
similar to that described for overexpression of Cpt-1b in
muscle, resulting in improved insulin sensitivity in mice
challenged with a HFD.
23 We speculate that CPT-1b
expressed in liver is out of its normal malonyl-CoA
regulatory milieu and would be constitutively more active
than the usual CPT-1a. This is likely because, CPT-1a is more
sensitive to hormonal changes, which increase or decrease
its sensitivity to malonyl-CoA in liver, unlike Cpt1b, which
is regulated solely by changes in the concentrations of
malonyl-CoA. The increased insulin sensitivity in the
CPT-1 þ/  mice, especially given the HFD challenge, was
more similar to our previous results in the very long-chain
acyl-CoA dehydrogenase-deficient mouse model.
14
Despite high Cpt-1b expression, we also found, however,
that microvesicular fatty change was significantly greater in
CPT-1aþ/  livers as compared with diet-induced liver
steatosis in CPT-1aþ/þ mice. However, CPT-1aþ/  mice
having greater amounts of microvesicular liver fat may not
be inconsistent with them being more insulin-sensitive. The
appearance of microvesicular fat is likely a consequence of
the FAO deficiency
24–26 that is unrelated to their heightened
insulin sensitivity.
27–29 This is further supported by a
previous study using CPT-1 inhibitor treatment in mice,
showing severe microvesicular fatty liver in the absence of
insulin resistance.
27 Furthermore, studies using mice with
Figure 5 Liver steatosis and Cpt-1b expression in CPT-1aþ/  and CPT-1aþ/þ mice. Representative images of micro- and macrovesicular fat in liver from (a) CPT
1aþ/  mouse and (b) CPT-1aþ/þ mice fed HCD. Representative images of micro- and macro vesicular fat in liver from (d) CPT 1aþ/  and (e) CPT-1aþ/þ mice
fed HFD. Quantitative real-time PCR analysis of Cpt-1b expression in liver as measured by QRT-PCR in (c) HFC-fed CPT-1aþ/  mice as compared with controls
(Po0.05) and (f) HFD-fed mice.
Table 3 Overall summary of results contrasting the CPT-1a+/  mice and their CPT-1a+/+ controls fed either the high carbohydrate or high fat diets
High-carbohydrate diet CPT1a+/  versus CPT-1a+/+ mice High-fat diet CPT1a+/  versus CPT-1a+/+ mice
Glucose tolerance More glucose tolerant No significant difference
Insulin secretion Higher first-phase insulin secretion Lower first phase at 28 weeks
No significant difference at 46 weeks
Insulin tolerance More insulin-sensitive More insulin-sensitive
Hepatic steatosis Increased microvesicular fat Increased microvesicular fat
Aberrant hepatic CPT-1b expression Increased No significant difference, trend is elevated
Pancreatic islet morphology Smaller islets Fewer islets
Body weight No significant difference Slightly lower
Body fat Higher Lower
Fasting insulin No significant difference Lower
Abbreviation: CPT, carnitine palmitoyltransferase
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demonstrated a dissociation between hepatic steatosis and
insulin resistance.
30
It may also be important to note that differences in glucose
and insulin tolerance, as well as fasting insulin levels
between the two genotypes and diets may also be explained
by different contributions of either hepatic or peripheral
sensitivity. As described previously by others,
3,22,31 in the
pre-diabetic state, insulin resistance could occur separately
and/or with different degrees in liver versus skeletal muscles,
and realized as either impaired fasting glucose or as impaired
glucose tolerance.
We measured size of islet by immunostaining b-cells for
insulin. We expected to see either hyperplasia or hypertro-
phy as a result of excessive secretion from a predicted fatty
acid build-up, or alternatively, a b-cell loss as a result of long-
term excess fatty acid exposure. We found that HFD-fed
CPT-1aþ/  mice had lower percent islet to pancreas area,
indicating that they did not have as many insulin-contain-
ing b-cells as did the CPT-1aþ/þ mice. The lower number of
b-cells could have been a result of apoptosis or reduction in
the production of insulin granules within the b-cells.
32,33 We
did not find degenerative lesions of islets in any of the
groups. A fatty acid-induced decreased b-cell function would
explain the decreased glucose tolerance found in HFD-fed
CPT-1aþ/  mice. In support of these conclusions, a recent
study demonstrating that overexpression of SREBP-1c in
b-cells, which resulted in b-cell triglyceride build-up, caused
the onset of impaired glucose tolerance, which these
investigators attributed partially to the reduction in number
and size of islets.
33
CPT-1aþ/  mice fed the HCD were also found to have
lower percent islet area/pancreas area, lower total islet area
and lower average islet area. In contrast to CPT-1aþ/  mice
fed the HFD, these mice were more glucose tolerant and had
higher first-phase insulin secretion, indicating that the lower
islet area either did not have an effect on their glucose
tolerance because of their heightened insulin sensitivity, or
that the lower islet area may have been a result of their
heightened insulin sensitivity. We interpret the global
reduction in islet mass as a response to the overall improved
insulin sensitivity as reflected in the CPT-1aþ/  mice fed
either diet.
In conclusion, CPT-1aþ/  mice were found to be more
insulin-sensitive when fed either a HCD or a HFD, which we
speculate may be explained by increased CPT-1b activity in
liver. Findings of lower fasting insulin levels in CPT-1aþ/ 
mice fed HFD for either 28 or 46 weeks further supported the
finding of increased insulin sensitivity from insulin toler-
ance testing. CPT-1aþ/  mice were more glucose tolerant
when fed the HCD but less glucose tolerant when fed the
HFD. We conclude that this difference was due to an
impaired insulin response to glucose as a result of both the
HFD and the FAO deficiency. This was further supported
by the results indicating that CPT-1aþ/  mice fed HFD
had lower percent islet/pancreas area, lower total islet area,
lower number of islets and lower average number of islets per
mm
2 of pancreas. In contrast, the CPT-1aþ/  mice fed HCD
were also found to have lower percent islet/pancreas area,
lower total islet area and lower average number of islets per
mm
2 of pancreas; however, they were still more glucose
tolerant, and this may be attributed to their greater insulin
sensitivity.
Thus, the interaction of the CPT-1a deficiency with either
HCD or HFD includes increased insulin sensitivity when fed
either diet along with enhanced b-cell responsiveness in
those fed the HCD, whereas, the HFD appeared to be
detrimental to b-cell response. There was a decrease in islet
cell mass in mutants fed either diet that corresponded with
their increased insulin sensitivity. These findings indicate
that it is the interaction between genotype and diet that
determines metabolic phenotype rather than diet or geno-
type alone. Therefore, full consideration of the genetic
determinants of disease risk should be considered in the
context of the individual genotype along with environment
and in this case the diet.
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